MRNA Stock News: Moderna has room to rally as coronavirus vaccine has five advantages over Pfizer's

  • NASDAQ: MRNA has surged after reporting promising interim results for its COVID-19 vaccine.
  • Moderna Inc's coronavirus immunization scheme has five advantages over Pfizer's. 
  • The shares' close above the previous peak is a promising technical indication. 

Does the early bird get the worm? Not necessarily. When it comes to the global race to beat COVID-19, there is room for various vaccine solutions to help the world emerge from the crisis. Thirst for any solution and production limits make every immunization scheme a winner at this point. 

What about the long run? When the world is saturated with vaccines, quality may make a difference. So far, only two efforts have announced promising interim results from their covid efforts, with Moderna Inc coming second after the initial announcement from Pfizer and BioNTech.

However, there are five reasons why Moderna has the edge:

1) Storage temperature: Any logistical hurdle can be surpassed, but a lower barrier makes life easier. While Pfizer's vaccine needs to be stored in ultracold -70 to -80 celsius ahead of the final five days before distribution, Moderna's inoculation can survive 30 days at +2 celsius. That makes distribution far easier. 

2) Efficacy rate: The difference between Pfizer's 90% and Moderna's 94.5% may sound like splitting hairs, but the PR effect of having a more efficient vaccine may encourage investors and also governments to opt for the latter. 

3) Diversity: Moderna's CEO Stéphane Bancel stressed that his company's solution has been tested among high-risk patients and those who come from different ethnic backgrounds. That makes the results more robust and immediately adequate for a larger audience. 

4) US government support: While Pfizer boasted about not taking money from Uncle Sam, Moderna has worked for hand in glove with the federal government. Dr. Anthony Fauci, America's top epidemiologist, was quick to hail Moderna's results. The backing of Washington – no matter the administration – is another win for Moderna. 

5) Expertise: Moderna is focused exclusively on the Messenger RNA technology – that was the vision of founders Robert S. Langer, Derrick Rossi, Kenneth R. Chien, Timothy A. Springer and Noubar Afeyan.That would allow them to upgrade their vaccine rapidly and potentially ramp up production.

All in all, Moderna Inc's vaccine seems to be set up for greater success. 

MRNA Stock Price

NASDAQ: MRNA closes at $97.95 on Monday, following the big news. As the chart shows, that is above the previous peak of $94.85 in July. The next target is $100.

Support awaits at $90, followed by $78.50, a high point in October. 

See What you need to know about the dollar in the post-vaccine announcement world

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

AUD/USD: Risks further downside despite holding 0.7700 after Powell-led losses

AUD/USD remains pressured near weekly low, drops for third consecutive day. Treasury yields soared even as Powell tried to ignore bond bears. Italy blocks AstraZeneca’s Aussie vaccine supply, NFP in focus.


EUR/USD nears February low as Fed's Powell not concerned about yields

EUR/USD is under strong selling pressure and nearing February monthly low at 1.1951 as Powell's words send US Treasury yields to fresh one-year highs, which in turn, boost the greenback. Wall Street in sell-off mode.


XAU/USD bounces off nine-month low below $1,700 but remains vulnerable

Gold bears catch a breather near the lowest since June 2020. Treasury yields stay strong near one-year top as Fed’s Powell joined the league of ECB but couldn’t placate bond bears.

Gold News

Ripple prepares for a 70% upswing

Ripple price shows signs of an upswing as it bounces off a stable support barrier around the $0.38 level. The “buy signal” from the SuperTrend indicator coupled with the bullish momentum suggests that a 70% upswing is possible.

Read more

US Dollar Index: Next on the upside comes in 91.60

DXY adds to recent gains and once again surpass the 91.00 mark, opening the door to a probable visit to multi-week peaks in the 91.35/40 band (March 2).

US Dollar Index News